WARSAW, Ind., July 11, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced that David C. Dvorak has stepped down as President and Chief Executive Officer and a member of the Board of Directors, effective today. To assist with the transition, Mr. Dvorak will serve in an advisory capacity to the Company for a period of time. The Board has appointed Daniel P. Florin, Senior Vice President and Chief Financial Officer, to serve in the additional role of Interim CEO and a member of the Board of Directors until a permanent successor has been named.

The Zimmer Biomet Board is retaining a leading executive search firm to identify and evaluate candidates for the permanent CEO role.

Mr. Dvorak said, “Serving alongside Zimmer Biomet’s dedicated employees over the past 16 years and leading the Company as CEO for ten of those years has been a privilege and a highlight of my professional career. Our collective efforts grew employment from approximately 3,000 in 2001 to 18,000 today and built a Fortune 500 company. I am particularly proud of what we have accomplished working together with surgeons and clinicians to help millions of patients globally improve their quality of life.”

Larry C. Glasscock, Chairman of the Board of Zimmer Biomet, commented, “During David’s ten-year tenure as CEO, Zimmer Biomet has transformed into a truly global leader in musculoskeletal healthcare. Through a combination of organic growth and strategic acquisitions, Zimmer Biomet’s revenue has doubled and the Company has established a leading portfolio of technologies, solutions and personalized services. With this strong platform in place, there is tremendous opportunity for Zimmer Biomet. On behalf of the Board, I thank David for his many important contributions to our Company and industry over the years and wish him much success in the future.”

Mr. Glasscock continued, “We are fortunate to have a leader of Dan’s caliber and experience to step into the CEO role on an interim basis while the Board conducts its search process. Dan’s knowledge of Zimmer Biomet and his achievements here and at other medical device companies make him an excellent choice to support the Company through this interim period. We appreciate his willingness to take on this expanded role.”

Mr. Florin said, “Zimmer Biomet has a talented and dedicated team and an unmatched portfolio. I am honored to assume the Interim CEO role and I look forward to working closely with the Board, senior leadership team and our sales force as we strive to support our customers and enhance stockholder value.”

About Dan Florin

Dan Florin was appointed Senior Vice President and Chief Financial Officer of Zimmer Biomet in June 2015 and has over 16 years of executive experience in the medical device industry. He previously served as Senior Vice President and Chief Financial Officer of Biomet from June 2007 to June 2015. Prior to joining Biomet, Mr. Florin served as Vice President and Corporate Controller of Boston Scientific Corporation from 2001 until 2007. Before being appointed Corporate Controller in 2001, Mr. Florin served in financial leadership positions within Boston Scientific Corporation and its various business units. Mr. Florin previously worked for C.R. Bard from October 1990 through June 1995, and Deloitte from September 1986 to October 1990. Mr. Florin holds a Bachelor’s degree in Business Administration with a concentration in Accounting from the University of Notre Dame and an Executive MBA from Boston University.

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All statements that address expectations, plans or projections about the future, including statements about Zimmer Biomet’s management transition plans, growth prospects and business strategy, are forward-looking statements.  Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially.  For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC).  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC.  Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in its periodic reports.  Accordingly, such forward-looking statements speak only as of the date made.  Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this news release.

ZBH-Corp

SOURCE Zimmer Biomet Holdings, Inc.

DRAPER, Utah, July 5, 2017 – Ortho Development^® Corporation (ODEV) is pleased to announce the signing of an agreement with China Pioneer Pharma Holdings Limited (CPP) as the exclusive distributor of ODEV’s Balanced Knee^® System in the People’s Republic of China.

China has recently surpassed Japan as the second largest market for orthopedic medical devices in the world. With an aging population and improvement in health insurance policies, the demand for total knee replacement procedures in China has been increasing rapidly. “Our strategic vision includes expanding distribution beyond the U.S. and Japanese markets into high-growth, emerging markets like China,” said Brent Bartholomew, President of ODEV. “We have been seeking the right distribution partner in China for quite some time, and are delighted to be working with an established, reputable partner like CPP.”

CPP is one of the largest comprehensive marketing, promotion and channel management service providers dedicated to importing pharmaceutical products and medical devices in China. Their portfolio includes ophthalmology, pain management, cardiovascular, respiratory, gastroenterology, immunology, orthopedics and other therapeutic areas, and a range of medical devices covering various medical specialties, including ophthalmology, odontology and wound care, etc. As of 31 December 2016, CPP sold products through its nationwide marketing, promotion and channel management service networks to approximately 30,000 hospitals and other medical institutions and over 108,000 pharmacies across all provinces, municipalities and autonomous regions in China.

Ortho Development’s Balanced Knee^® System (BKS) includes implants and instrumentation for primary and revision total knee replacement procedures. The design is based on proven technology with over 17 years of successful clinical results and more than 70,000 implanted worldwide. BKS implants are offered in a wide range of sizes and options to allow optimal anatomical fit for a variety of patients. The system has a patented locking mechanism specifically designed to minimize the micro-motion between the plastic tibial insert and the titanium tibial base plate implants. Simple and intuitive instrumentation facilitates reproducibility in the hands of every surgeon and aides in proper intraoperative balancing of the knee joint.

The medical device registration in China for the BKS has already been completed, and CPP intends to begin marketing the product immediately. Following the tender and bidding process with specific hospitals, CPP expects the first knee replacement procedures in China with BKS will occur in early 2018.

About Ortho Development Corporation

Ortho Development Corporation was founded in 1994 and is a privately held company located in Draper, Utah, U.S.A. The company is passionate about designing and manufacturing the best, clinically proven, high-performance orthopedic devices in the world. The primary product focus is total knee and hip joint replacement; and also includes trauma fracture repair, and spine treatment. Ortho Development products are distributed through a growing network of independent sales reps and distributors and are used by hundreds of surgeons at world-renowned orthopaedic hospitals and teaching universities, as well as in a widespread number of regional and community hospitals. The company’s majority shareholder is Japan Medical Dynamic Marketing, Inc. (Japan MDM), a publicly-traded, Japanese medical device distribution company.

7/6/2017

TAMPA, Fla. – Corin, a global manufacturer of orthopedic devices and high-tech solutions to improve surgical procedures, today announced that it will expand its US headquarters in Tampa. The company will up to 100 new high-wage jobs in marketing, operations, sales and other administrative roles and invest $500,000 in its new offices by 2022.

“We are fortunate to have such strong growth, which has enabled rapid expansion of our staff and facilities,” said Paul Berman, president of Corin USA. “Tampa has been and will continue to be a corridor of technological and healthcare innovation, which creates a strong base for talent and collaborative partnerships with other adjacent industries.”

Corin USA is a wholly-owned division of the 34-year-old British medical device company Corin Group LLC, located in Cirencester, UK.  Corin USA was established 14 years ago in Tampa and is home to the company’s business activities in the US. Sales, marketing, clinical, regulatory, finance, and operations and logistics groups supporting the sales and marketing of Corin’s medical devices and technologies throughout the US are located at its regional office in Tampa.

Corin USA, which employs 30 individuals locally and over 100 across the US, moved this month from offices on West Cypress Street to 7,000 square feet of new space at 12750 Citrus Park Lane, Suite 120, Tampa, FL 33625.

As a leader in orthopedic innovation, Corin has pioneered a number of landmark developments since its inception in 1985. The company has improved the quality of life of hundreds of thousands of patients across the world through the introduction of its groundbreaking products.

In March 2017, Corin introduced its revolutionary Optimized Positioning System (OPS™) System at the American Academy of Orthopaedic Surgeons (AAOS) in San Diego. The technology may lead to one of the most significant changes to the way hip replacements are performed in more than 30 years.

The first-ever functional, patient-specific hip replacement procedures using OPS were performed in the US in November 2016, shortly after FDA clearance. More than 3,000 procedures have been done already in Europe and Australia, where the system was previously approved for use.

“No two patients are the same, so Corin is offering a patient-specific solution that gives the surgeon the information and tools necessary to enable an optimal hip replacement procedure based on each individual patient’s unique anatomy,” said Berman. “Feedback from surgeons who have used OPS has been excellent and interest in the system from the orthopedic community is very high.”

The Tampa Hillsborough Economic Development Corporation assisted Corin USA with its real estate property search as well as connections to workforce training programs and expedited permitting services.

“Hillsborough County’s life sciences sector is booming,” said Dr. Ken Atwater, chairman of the Tampa Hillsborough Economic Development Corporation and president of Hillsborough Community College. “The success that companies like Corin are enjoying is elevating our global reputation as an attractive location for others in this industry. Tampa offers Corin a highly skilled talent pool, close proximity to an exceptional international airport, and a business climate that supports their growth. We are proud to partner with Corin as they expand and thank them for bringing more great jobs to our community.”

Individuals interested in available jobs may refer to the company’s career website, here.

About Corin Group

Corin is a European orthopedic manufacturer based in the United Kingdom that markets its products throughout the world. Corin is committed to improving patient satisfaction with personalized technologies that optimize our clinically proven joint replacements; delivering a personal approach to our customers, combining the spirit of our local companies with the strength of our global, integrated organization; and empowering and rewarding our global talented teams to deliver excellence to our customers.

For further information about Corin, please visit www.coringroup.com.

About the Tampa Hillsborough Economic Development Corporation

The Tampa Hillsborough Economic Development Corporation is the lead designated economic development agency for Hillsborough County and the cities of Tampa, Plant City, and Temple Terrace. Established in 2009 as a partnership between the public sector and private corporate investors, the EDC works to develop and sustain a thriving local economy through the attraction, retention and expansion of high wage jobs and capital investment within targeted industry sectors.